Home  |  Site Map  | Contact
FEB. 5

QLT Annouces Closing of Acquisition of Shares of Aralez Pharmaceuticals Inc. and Special Distribution to Shareholders

   
Jan.12

QLT Announces Results of Annual Meeting of Shareholders

   
DEC.28

QLT Calls Special Meeting of its Shareholders in Connection with Aralez Pharmaceuticals Transaction


   
DEc.16

QLT Commences Breach of Contract Action Against Valeant Pharmaceuticals

   
Dec. 7

QLT, Deerfield and Other Leading Healthcare Investors Confirm Their Planned Investment in Aralez Pharmaceuticals

   
   
   
   
   
   
   
   
 

To view the “Clinical Proof-of-Concept Study of Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.

 
 
To view the “Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.
   
 
2014 Annual Report
For the Annual Report for the fiscal year ended December 31, 2014, click here.
   
   
   
   
   
   
 
Copyright 2000-2015 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss